Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer - Test2 - elhamkhani - TriplyDB

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer

http://www.wikidata.org/entity/Q26858922

about

Advances in genetics: widening our understanding of prostate cancer When Prostate Cancer Circulates in the Bloodstream Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer Using circulating tumor cells to inform on prostate cancer biology and clinical utility Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer Registered report: the androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7 Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells.Androgen receptors beyond prostate cancer: an old marker as a new target.Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.Diagnostic value of SFRP1 as a favorable predictive and prognostic biomarker in patients with prostate cancer.Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance Androgen receptor splice variants and polycystic ovary syndrome: cause or effect?Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.Androgen receptor splice variants in the era of enzalutamide and abiraterone.FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.Downregulation of androgen receptors by NaAsO2 via inhibition of AKT-NF-κB and HSP90 in castration resistant prostate cancer.Androgen receptor aberrations in the era of abiraterone and enzalutamide.Recepteur d'origine nantais (RON), more than a kinase: Role in castrate-resistant prostate cancer.New advances in genitourinary cancer: evidence gathered in 2014.Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer.Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture.Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer.Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer Androgen Signaling in Prostate Cancer.AR Signaling and the PI3K Pathway in Prostate Cancer Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.

P2860

Q26740628-971C74B4-EBD1-4DF0-A084-2B67A9F7DC8D Q26768470-5F41A274-487B-4A50-9961-2BEBF311D4D2 Q26777310-4BB33FA2-4449-46EF-8A83-CA50DBFB145D Q26795625-2BA19DEE-4929-42D7-B3F4-F07E542051EB Q28083261-8FAC66CB-4F06-41A0-A2F5-E250FC0FD0AE Q28278828-B6334902-9D82-4FDD-B753-687625823BDD Q28607383-08DFFE77-05CA-401F-9D46-0FD961FB1584 Q28607387-6C84D252-2362-49D4-987A-E3B27A5C406C Q30370955-C0671AB0-E608-45FD-975E-30DCFFA310D7 Q33821011-73DE1A75-12BD-4444-93A0-5358A4958CE4 Q34458538-289C8A3D-D62E-48A3-9927-4D7C4B093CB8 Q34550412-68B88F11-4391-4B2B-A540-ABE911D0635A Q35568239-CC2722A5-9CEC-4273-94F2-5680CF254F6D Q35842471-88A677E7-FCA7-4701-9AA4-4AC010B2CD20 Q36398998-E3118725-8AFC-4360-99FA-B2B3D04238DA Q36407003-542281C6-D386-483E-BDCD-C780B08ED283 Q36470627-0B16C529-E548-43FE-AD28-9788CCFB2B1D Q36861589-6A48939C-CCA9-48EE-A8BA-98C8E11A1C06 Q37550588-97B4486F-BD46-4DDC-A6C4-E8B180D5816A Q38232413-D162E321-9AB3-4291-9E2D-048927A2ABB9 Q38286227-E43501EC-B486-4DBD-AC4F-E77AD5DDD5F2 Q38298274-DC7D4B88-DFDD-4309-8B70-2B45DBD929CC Q38402398-7FDAF28F-A45B-406C-B2A0-B6613E3A5291 Q38534949-03C2D54C-BE20-48ED-8C91-C746AB5455D1 Q38543678-E4A1A3EE-BB70-4A8D-B260-3CD2F59D4BE9 Q38557894-029CB34B-687E-497E-B01E-9F279A1D07EE Q38678110-5660EA54-D52D-49B7-A239-32FA903A7EE1 Q38703676-88BD563D-9E3C-4F5F-AB9D-8D5D283FEF52 Q38748082-94C68715-EE3B-4009-ACAD-B4986A6648D2 Q38769817-E18AFCA5-6041-47D2-BAA8-542B555CD3A0 Q38797560-F8B6B3FA-FC7C-4410-B269-A128BFF821E2 Q38833356-BFBA87D7-332E-433E-B9A2-15D6AE0F293A Q38835693-5F6E2A74-0E69-4F9A-989E-DEBF75F5F057 Q38843958-385CDD36-8572-4E0D-A535-1D418A496A6A Q38958184-1251C410-F250-43A5-996E-4E6D393AE8F0 Q39227656-0DDF7A25-7ECD-4B15-A9F0-2FC33F11B049 Q39249001-0E23E60F-9C5C-48FC-AFAC-FA779E2DB808 Q39819392-72A4EC11-E96A-4DBD-875E-AB065674D467 Q40423383-4BFA224C-D14D-4C2D-A5EF-2A035EB0E88B Q41270542-DF17CCFB-8D65-4246-B8A0-A4165A8EE424

P2860

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer

http://www.wikidata.org/entity/Q26858922

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Biologic and clinical signific ...... tion resistant prostate cancer

@ast

Biologic and clinical signific ...... tion resistant prostate cancer

@en

Biologic and clinical signific ...... tion resistant prostate cancer

@nl

type

label

Biologic and clinical signific ...... tion resistant prostate cancer

@ast

Biologic and clinical signific ...... tion resistant prostate cancer

@en

Biologic and clinical signific ...... tion resistant prostate cancer

@nl

prefLabel

Biologic and clinical signific ...... tion resistant prostate cancer

@ast

Biologic and clinical signific ...... tion resistant prostate cancer

@en

Biologic and clinical signific ...... tion resistant prostate cancer

@nl

P1433

Q26858922-1F8928D2-0F32-4476-B49E-1D8D992B73F3

P1476

Q26858922-C45B167E-3E3A-4791-BFE9-8F09736EABD9

P2093

Q26858922-199866A0-2C21-42D0-9F4A-D7BA0F6BA942

Q26858922-1EDA4D11-DF90-4D81-9C54-6784EC56D6DE

Q26858922-2D7703A1-B525-49C5-8DDB-8F8D38C322BC

Q26858922-58CF8431-B5A5-42F5-8E31-488D57955FBF

P2860

Q26858922-096950B2-5332-4AB2-9B76-2981E6295EE7

Q26858922-0A878FB1-B477-48E2-ADD7-AA84EEC51853

Q26858922-171C5D58-E02A-4C7A-835A-E703B10614ED

Q26858922-1A7BB6C8-3C2C-4517-94F2-37519077D3FC

Q26858922-1C6A1E59-FA73-4AEB-A599-FB3ECB7E5C48

Q26858922-2545EC29-5D2C-411D-9BD4-BF81E7728B2A

Q26858922-26313DFE-2F1B-4621-B155-7C50861FAC73

Q26858922-28363FD5-4A57-4C32-B54A-AA355FFB8D48

Q26858922-2C8A94CE-1ECE-4AD0-9C64-80E7D89ECB4F

Q26858922-2D163D6C-74CC-4CD9-8D82-CC05173FF79E

P304

Q26858922-0CAE776A-FB5A-4B46-8CE5-B5EA81ACC84D

P31

Q26858922-AEC58A99-6AA4-427A-8ECB-17B336D12C61

P3181

Q26858922-0A43128A-0F58-4FD0-A837-4C8C31F1F5A4

P356

Q26858922-FE9B0C00-F3D5-429E-B3B7-F5B5588A25E0

P407

Q26858922-2E289F7C-09F8-4558-81FA-0DD16C5B597C

P433

Q26858922-3AD3ABA4-ADEE-434F-928F-3C23D3CF9518

P478

Q26858922-84322CA6-9400-4054-B8CD-5B3A2A17C4F8

P577

Q26858922-4B13ABBE-BC48-41FE-ADD2-149DBF846EE6

P698

Q26858922-C0AE45DC-E062-4E1F-B15C-58923C8105EE

P932

Q26858922-088813E6-B6BC-4464-9A39-F24645C6FA89

P3181

P356

P1433

Endocrine-related cancer

P1476

Biologic and clinical signific ...... tion resistant prostate cancer

@en

P2093

A. J. Armstrong

http://www.w3.org/2001/XMLSchema#string

K. E. Ware

http://www.w3.org/2001/XMLSchema#string

M. A. Garcia-Blanco

http://www.w3.org/2001/XMLSchema#string

S. M. Dehm

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases

An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

Wnt5A activates the calpain-mediated cleavage of filamin A

Identification of a cell of origin for human prostate cancer

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Abiraterone in metastatic prostate cancer without previous chemotherapy

The genomic complexity of primary human prostate cancer

P304

T87-T103

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1658201

http://www.w3.org/2001/XMLSchema#string

P356

10.1530/ERC-13-0470

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24859991

http://www.w3.org/2001/XMLSchema#string

P932

4277180

http://www.w3.org/2001/XMLSchema#string